UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/687,788	10/17/2003	Shamci Monajembashi	SHA-001	9873
3897 SCHNECK & S	7590 03/12/200 SCHNECK	EXAMINER		
P.O. BOX 2-E	. 05100.0005	WHALEY, PABLO S		
SAN JOSE, CA 95109-0005			ART UNIT	PAPER NUMBER
			1631	
			MAIL DATE	DELIVERY MODE
			03/12/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/687,788	MONAJEMBASHI, SHAMCI				
Office Action Summary	Examiner	Art Unit				
	PABLO WHALEY	1631				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on <u>05 De</u>	ecember 2007					
	action is non-final.					
·=						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
- 4)⊠ Claim(s) <u>1-19, 21, 24-26, 28 and 29</u> is/are pending in the application.						
4a) Of the above claim(s) <u>1-15 and 27</u> is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>16-19,21,24-26,28 and 29</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correcti	• ,	, ,				
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12)☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1.☐ Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau	ı (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	nte				
Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	αιστι πρμιταιίστ				

Application/Control Number: 10/687,788 Page 2

Art Unit: 1631

DETAILED ACTION

1. In view of the appeal brief filed on 12/05/2007 and an updated search of the prior art,

PROSECUTION IS HEREBY REOPENED. Newly applied rejections are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following two

options:

(1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37 CFR

1.113 (if this Office action is final); or,

(2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an appeal

brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee can be applied to

the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have been increased since they

were previously paid, then appellant must pay the difference between the increased fees and the amount

previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing below:

/Marjorie Moran/

Supervisory Patent Examiner, Art Unit 1631

Claims Under Examination

Claims herein under examination are claims 16-19, 21, 24-26, 28 and 29. Claims 20, 22, and 23

have been cancelled. Claims 1-15 and 27 remain withdrawn from further consideration pursuant to 37

CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking

claim

The rejection of claim 18 under 35 U.S.C. 112, second paragraph is withdrawn in view of

applicant's arguments filed 11/20/2006.

The rejection of claims 16-19, 21, 24-26, and 28 are rejected under 35 U.S.C. 103(a) as being

made obvious by Henon et al. (Biophysical Journal, 1999, Vol. 76, p.1145-1151), in view of Jan et al.

(THE JOURNAL OF GENERAL PHYSIOLOGY, 1973, Vol. 61, p. 638-654) is withdrawn in view of

applicant's arguments filed 12/05/2007.

The rejection of claims 16-19, 21, 24-26, 28 and 29 under 35 U.S.C. 103(a) as being made

obvious by Visscher et al. (Cytometry, 1993, Vol. 14, p.105-114), in view of Jan et al. (The Journal Of

General Physiology, 1973, Vol. 61, p. 638-654) and Shaw et al. (Cellular Microbiology, 2001, Vol. 3, No.

4, p.213-222) is withdrawn in view of applicant's arguments filed 12/05/2007.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C.102 that form the basis for the

rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or

in public use or on sale in this country, more than one year prior to the date of application for

patent in the United States.

Claims 16-17, 19, 21, 24-26, and 28 are rejected under 35 U.S.C. 102 (b) as being anticipated by

Bronkhorst et al. (British Journal of Haematology, 1997, Vol. 96, p.256-258). This rejection is newly

applied.

Bronkhorst teaches a method for studying cell-cell interaction in between red blood cells (i.e. erythrocytes) [Abstract]. An optical tweezer system is disclosed in detail [p.256, Methods] and includes a 1064-nm laser beam and microscopic imaging capabilities [Fig. 1], as in claims 19, 21, 26, 27, and 28. It is noted that the specification [p.8] defines a long-wave laser beam to be between 700 and 1100 nm, therefore Bronkhorst teaches this limitation. In particular, Bronkhorst teaches applying two optical traps (i.e. multiple laser beams) to red blood cells in order to bring them together, allowing a brief period of aggregate formation wherein cells are attached, and then pulling cells apart using optical tweezers [p.256, Col. 2, last ¶]. Therefore, Bronkhorst provides steps for applying optical tweezers and adhering as in claims 16, 19, 21, 24, and 25. Bronkhorst also provides a list [Table 1] of substances used that change the surface charge of the erythrocytes, and discloses that an anticoagulant was used to treat cells prior to experimentation [p.256, Col. 2, ¶3]. Therefore claim 17 is anticipated since cells inherently have surface charges with differing signs.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 16, 17, 19, 21, 24-26, 28 and 29 are rejected under 35 U.S.C. 103(a) as being made obvious by Bronkhorst et al. (British Journal of Haematology, 1997, Vol. 96, p.256-258), in view of Visscher et al. (Cytometry, 1993, Vol. 14, p.105-114). *This rejection is newly applied*.

Bronkhorst teaches a method for studying cell-cell interaction in between red blood cells (i.e. erythrocytes) [Abstract]. An optical tweezer system is disclosed in detail [p.256, Methods] and includes a 1064-nm laser beam and microscopic images [Fig. 1], as in claims 19, 21, 26, 27, and 28. It is noted that the specification [p.8] defines a long-wave laser beam to be between 700 and 1100 nm, therefore Bronkhorst teaches this limitation. In particular, Bronkhorst teaches applying two optical traps (i.e. multiple laser beams) to red blood cells in order to bring them together, allowing a brief period of aggregate formation wherein cells are attached, and then pulling cells apart using optical tweezers [p.256, Col. 2, last ¶]. Therefore, Bronkhorst provides steps for applying optical tweezers and adhering as in claims 16, 19, 21, 24, and 25. Bronkhorst also provides a list [Table 1] of substances used that change the surface charge of the erythrocytes, and discloses that an anticoagulant was used to treat cells prior to experimentation [p.256, Col. 2, ¶3]. Therefore Bronkhorst shows surface charges with differing signs.

Bronkhorst does not specifically teach the use of a confocal microscope.

Visscher et al. teach the use of a confocal scanning laser system for the micromanipulation of cells [Abstract] by inducing optical forces for manipulating a target comprising a confocal microscope, multiple beams, optical tweezers, and long wave beams [Fig. 1], [p.106, Col. 2, ¶ 3], and [p.112, Col. 2, ¶ 2]. Visscher et al. also teach unique multi-trap technique that provides a benefit of indirectly trapping biological objects using optical tweezers and multiple cells [p.113, Col. 1, ¶ 4 and Col. 2, ¶ 1] and [Fig. 7].

It would have been obvious to someone of ordinary skill in the art at the time of the instant invention to practice the method of Bronkhorst using the confocal cell trapping system of Visscher et al.,

since Bronkhorst teaches multiple optical traps for cell manipulation, as shown above. The motivation to combine the above references is provided by Visscher [p.113, Col. 1], who show a unique technique for trapping multiple erythrocytes, resulting in the practice of the instant claimed invention.

Claims 16 and 18 are rejected under 35 U.S.C. 103(a) as being made obvious by Bronkhorst et al. (British Journal of Haematology, 1997, Vol. 96, p.256-258), in view of Kelm et al. (Glycoconjugate Journal, 1994, Vol. 11, p.576-585). *This rejection is newly applied.*

Bronkhorst teaches a method for studying cell-cell interaction in between red blood cells (i.e. erythrocytes) [Abstract]. An optical tweezer system is disclosed in detail [p.256, Methods] and includes a 1064-nm laser beam and microscopic images [Fig. 1], as in claims 19, 21, 26, 27, and 28. It is noted that the specification [p.8] defines a long-wave laser beam to be between 700 and 1100 nm, therefore Bronkhorst teaches this limitation. In particular, Bronkhorst teaches applying two optical traps (i.e. multiple laser beams) to red blood cells in order to bring them together, allowing a brief period of aggregate formation wherein cells are attached, and then pulling cells apart using optical tweezers [p.256, Col. 2, last ¶]. Therefore, Bronkhorst provides steps for applying optical tweezers and adhering as in claims 16, 19, 21, 24, and 25. Bronkhorst also provides a list [Table 1] of substances used that change the surface charge of the erythrocytes, and discloses that an anticoagulant was used to treat cells prior to experimentation [p.256, Col. 2, ¶3].

Bronkhorst does not specifically teach the use of fixed erythrocytes.

Kelm teaches the use of fixed and non-fixed erythrocytes in cell binding experiments [p.577, Col. 2, and p.578, Col. 1, ¶2].

It would have been obvious to someone of ordinary skill in the art at the time of the instant invention to practice the method of Bronkhorst using fixed erythrocytes as shown by Kelm, where the

motivation would have been to use a well known technique for preserving cells for experimentation, as

suggested by Kelm [p.578, Col. 1, ¶2], resulting in the practice of the instant claimed invention with

predictable results.

Response to Arguments

Applicant's arguments, filed 11/20/2006, regarding Visscher are moot in view of the new ground(s) of

rejections. These rejections are necessitated by amendment.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should

be directed to Pablo Whaley whose telephone number is (571)272-4425. The examiner can normally be

reached on 9:30am - 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor,

Marjorie Moran can be reached at 571-272-0720. The fax phone number for the organization where this

application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/687,788 Page 8

Art Unit: 1631

Information regarding the status of an application may be obtained from the Patent Application

Information Retrieval (PAIR) system. Status information for published applications may be obtained

from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-

direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Pablo S. Whaley/

Patent Examiner

Art Unit 1631

/John S. Brusca/

Primary Examiner, Art Unit 1631